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INTRODUCTION
Pregnancy-induced hypertension (PIH) usually develops
during the second half of the pregnancy and accompanies
proteinuria and edema. PIH is estimated to affect 7 to 10%
of all pregnancies in the United States (1), making common
complications associated with feto-maternal death and mor-
bidity. 
While the etiology of PIH remains unclear, it is known
to be associated with endothelial damage and dysfunction (2).
There are also an increased concentration of vasoconstrictive
agents such as endothelin (3), increased capillary permeabil-
ity (4), and the endothelial damage is also associated with neu-
trophil (5). 
An impaired trophoblastic invasion of the maternal placen-
tal bed is considered to be the initiator of endothelial damage
in PIH (6). This defect might result in poor fetoplacental per-
fusion along with a release of factors into the maternal circu-
lation, leading to a widespread endothelial damage and the
resulting clinical symptoms of PIH (7). This placental dys-
function could be mediated by the factors present in the mater-
nal circulation as a result of impaired trophoblastic invasion
(6). Angiogenic growth factors are also thought to play a sub-
stantial role in the placentation, and can be strong endothe-
lial cell activators (8).
Recently, placenta growth factor (PlGF), a dimeric secret-
ed factor that shares close amino acid homology (53% iden-
tity) to vascular endothelial growth factor (VEGF), was known
as a potent angiogenic growth factor capable of inducing the
proliferation, migration, and activation of endothelial cells
(9). Unlike VEGF, abundant expression of PlGF is restrict-
ed to the placenta (10). Alternative splicing of PlGF mRNA
produces at least three polypeptides, PlGF-1, PlGF-2 and
PlGF-3, which have different secretory patterns, heparin-
binding affinities and dimerization properties (10, 11).
Ideal placental development requires an adequate and orga-
nized interaction of vascular growth factors and their recep-
tors, including VEGF and PlGF; both VEGF and PlGF act
through their common tyrosine kinase receptors (12). The
expression of VEGF and KDR (PlGFR-2/VEGFR-2) is stron-
gest during early gestation and decrease as pregnancy advances
(13-15) while PlGF and Flt-1 (PlGFR-1/ VEGFR-1) increase
towards term (16, 17). In the present study, we examined the
expression patterns and localization of PlGFs and their recep-
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Placental development requires extensive angiogenesis and the invasion of the
maternal decidua by the trophoblasts. Adequate and organized interaction of vas-
cular endothelial growth factors (VEGF), placenta growth factors (PlGF), and their
receptors are essential for a normal development and function of the placenta.
In this study, we evaluated the expressions of PlGFs and their receptors, mRNAs
by Northern blotting, in situ hybridization and RT-PCR in the normal and pregnan-
cy-induced hypertensive (PIH) placentas. The expression level of PlGF-2 mRNA
was lower in the PIH placentas compared to control as assessed by Northern blot-
ting and in situ hybridization. PlGF mRNA was mainly localized to the vasculosyn-
cytial membrane of placental villi and villous stroma. The expression of PlGF recep-
tor-1 (PlGFR-1) was significantly increased in the PIH placentas compared to the
normal ones. These results suggest that the alteration of PlGF-2 and PlGFR-1
mRNA expressions in the placenta are related to the pathogenesis of PIH.
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MATERIALS AND METHODS
Tissue collection and preparation for in situ hybridiza-
tion
Placentas used for analyses were collected from 8 normal
[37 (4 cases), 38 (2 cases), 39 wk (2 cases)] and 5 PIH [36
(2 cases), 37, 38, 39 wk] mothers at caesarean section deliv-
ery in Gyeongsang National University Hospital (GNUH).
The Human Subject Research Committee of GNUH approv-
ed these human tissues for the present study. The parameters
to define PIH were systolic, and diastolic blood pressures above
140 and 90 mmHg, respectively, in at least two consecutive
measurement, and proteinuria of >0.3 g/24 hr, in women after
20-week of gestation. The placentas (approximate weight:
100 mg) were snap frozen in liquid nitrogen immediately
after collection for total RNA extraction. For in situ hybridiza-
tion, the placentas were dissected on ice, cut into cubes fit into
slide glass, and washed with phosphate buffered saline (PBS,
pH 7.0). And then those tissues were post-fixed by a 48 hr-
immersion in 4% neutrally buffered paraformaldehyde and
cryoprotected by immersion in 20% sucrose in PBS for 24
hr. The tissues were frozen using OCT compound (Sakura
Finetek, CA, U.S.A.), and 12  m sections were cut with a
cryostat (Leica, Heidelberger, Germany) and thaw-mounted
on gelatin-coated slides, dried and stored at -70 until use.
Hematoxylin and eosin staining
The frozen sections were washed with tap water for 5 min,
immersed in hematoxylin for 2 min and checked for complete
staining in tap water. Eosin staining was carried out for 3 min.
Sections were dehydrated through a graded series of alcohol
(70 to 100% ethanol, 3 min each), cleared in xylene, cover-
slipped and observed with a light microscope.
Northern blot analysis
Total RNA was extracted from placenta, using acid guani-
dium thiocyanate-phenol chloroform method, and quanti-
fied by UV spectrophotometer. Twenty micrograms of total
RNA was subjected to electrophoresis in a 1.2% agarose-
formaldehyde gel and then capillary-transferred to a nylon
membranes (Nytran, pore size: 0.45  m, Schleicher & Schuell,
Keene, NK). The partial cDNAs of human PlGF-1/-2 were
obtained form human placenta using RT-PCR and cloning.
Then we confirmed PlGF cDNAs after sequence analysis and
used as template for probe synthesis. Probes were labeled by
random priming with [32P]-dCTP, and purified with a
Sephadex G-50 nick column (Pharmacia Biotech, Uppsala,
Sweden). Hybridization was carried out for 16-18 hr at 42
in 20 mL of hybridization buffer [50% Deionized Formamide,
5 SSPE (20 SSPE: 3 M NaCl, 0.2 M NaH2PO4, and 20
mM EDTA, pH 7.4), 5 Denhardt' s solution (1 Denhardts
solution, 0.02% polyvinyl-pyrolidone, 0.02% Ficoll, 0.02%
BSA), 0.1% SDS, 1 mg/mL heated-denatured salmon sperm
DNA]. Membranes were washed in 2 SSPE with 0.1% SDS
at room temperature for 10 min twice and in 0.1 SSPE
with 0.1% SDS at 42 for 10 min. The membranes were
exposed to radiography film (Fuji RX & Fuji Co, Tokyo,
Japan) for 3 days at -70
In situ hybridization
The 35S-UTP-labeled probes were generated by in vitro tran-
scription from partial cDNA clone amplified from PIH pla-
centas. The probes were purified with Sephadex G-50 nick
column and radioactivity was measured on a  -counter. Pre-
hybridization was carried out for 1 hr at 37 in prehy-
bridization buffer [50% Deionized Formamide, 0.25 M
NaCl, 1 Denhardts solution, 10 mM Tris (pH 8.0), 1 mM
EDTA (pH 8.0), 10% Dextran Sulfate, yeast tRNA (250  g/
mL), 50 mM DTT]. Hybridization of the slides with anti-
sense  35S-UTP-labeled RNA transcripts (7 105 cpm per
section) in prehybridization buffer was performed at 60
for 20 hr. Sections were washed in 4 SSC, treated with 20
g/mL of RNase A, washed in 2 SSC, and followed with a
further wash in 0.1 SSC containing 1.0 M DTT at room
temperature. Sections were dehydrated through a graded
series of alcohol (50% to 100% ethanol) and air dried at
room temperature, then autoradiographed for 7 days at -70
using Amersham  -max hyperfilm (Amersham, NJ,
U.S.A.). Slides were then dipped in NTB2 autoradiographic
emulsion (Kodak, NY, U.S.A.) and exposed in the dark at 4
for 14 days, and developed with D-19 developer, fixed
with rapid fixer (both from Kodak, NY, U.S.A.), counter-
stained with cresyl violet, and mounted.
RT-PCR analysis of PlGFR-1 and PlGFR-2 mRNAs
Complementary DNA was synthesized in a mixture con-
sisting of 1  g total RNA from each placenta, 200 unit of
RNaseH Muloney murine leukemia virus (MMLV) reverse
transcriptase (Promega, Madison, WI, U.S.A.) in 20  L of
the RT reaction mixture [150 pmol of oligo d(T), 40 units
of RNase inhibitor, 50 mM Tris-HCl (pH 8.3), 75 mM
KCl, 3 mM MgCl2, 1 mM dNTPs (N=A, T, G, and C), and
10 mM DTT] at 37 for 1 hr, followed by 5 min at 95 .
After heat inactivation, cDNA (total 20  L) was stored at
-20 until PCR.
The PCR reaction mixture (50  L) containing 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 25 mM MgCl2, 2 units of
Taq polymerase, 0.2 mM dNTPs, 4  L of each placental
cDNA, and 10 pmol of each specific PCR primer for
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3 , downstream; 5 -TTTCTTCCCACAGTCCCAAC -3 ) and
PlGFR-2 (upstream; 5 -TGTATGTCCCACCCCAGATT-
3 , downstream; 5 -ACATTTGCCGCTTGGATAAC-3 )
were added. The PCR reaction mixture was subjected to 30
cycles of amplification using a PCR system with denaturation
at 94 for 1 min, primer-annealing at 55 for 1 min, and
primer-extension at 72 for 2 min. PCR products (10  L)
were subjected to electrophoresis in a 1.2% agarose gel in TAE
buffer, visualized by UV illumination after ethidium bromide
staining, and photographed using Polaroid 667 film (Hert-
fordshire, U.K.).  -actin was used as a internal control for pro-
cedual variation. The intensity of PCR bands was measured
densitometrically and analyzed using SigmaGel (version 1.0,
Jandel Scientic Software) software.
Statistics
RT-PCR signals were normalized to their  -actin signals.
One-way analysis of variance was determined using Graph-
pad Instat Software (Version 1.15). A p value<0.05 was
deemed statistically significant; data are expressed as mean
SEM.
RESULTS
H & E staining in the normal and PIH placentas
Representative hematoxylin and eosin-stained sections of
the normal and PIH placentas were shown in Fig. 1. In the
PIH placenta, specific histologic changes were seen compared
to control; the syncytial membranes were continuously expand-
ed and the number of syncytial knots was increased in the
PIH placental villi.
Expression of PlGF-1 and PlGF-2 mRNAs in the nor-
mal and PIH placentas
Northern blot analyses were conducted to evaluate differ-
ences in the abundance of PlGF-1 and PlGF-2 mRNA in
normal and PIH placentas. Both PlGF-1 and PlGF-2 mRNAs
were less abundant in PIH placenta compared to normal
(Fig. 2); of two genes, the PlGF-2 was markedly decreased
(Fig. 2B).
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A B
Fig. 1. Photographs of H & E staining in the normal and PIH (pregnancy induced hypertension) placentas. Note the thickening of syncytial
membranes, an increased number of syncytial knots (arrow) of the placenta villi in the PIH placenta as compared to control. (A) normal
placenta; (B) PIH placenta. Scale bar= 100  m.
Fig. 2. Expression of PlGF-1 and PlGF-2 mRNA in the normal and
PIH (pregnancy induced hypertension) placentas as assessed
by Northern blot analyses. Northern blotting shows a 1.4- (PlGF-1)
and a 1.7-kb (PlGF-2) transcript in the normal and PIH placenta
after a hybridization with PlGF-1- and PlGF-2-specific cDNA
probes, respectively. PlGF2 mRNA is markedly decreased in the
PIH placenta compared to the normal placenta. Twenty micro-
grams of total RNA from the pool of 8 normal and 5 PIH placentas
was applied to each lane, and the consistency in loading is demon-
strated by ethidium-bromide staining of 18S rRNA. PlGF-1, pla-
centa growth factor -1; PlGF-2, placenta growth factor -2.
A B
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Normal     PIH
18S 18S
Normal     PIH
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PIGF-2Localization of PlGF-1 and PlGF-2 mRNAs in the nor-
mal and PIH placentas by in situ hybridization
The PlGF-1 (data not shown) and PlGF-2 mRNAs were
localized in the vasculosyncytial membrane and the villous
stroma of placental villi in the normal (Fig. 3A) and PIH
placenta (Fig. 3B). While no significant difference was detect-
ed in the expression of PlGF-1 mRNA between normal (Fig.
3a) and PIH placentas (Fig. 3b), the expression of PlGF-2
mRNA was decreased in the PIH placenta (Fig. 3d) compared
to the normal one (Fig. 3c).
Expression of PlGFR-1 and PlGFR-2 mRNAs in the
normal and PIH placentas
The mRNAs encoding PlGFR-1 and PlGFR-2 were detect-
ed by RT-PCR in both the normal and PIH placentas. While
the expression of PlGFR-1 was significantly higher in the
PIH placentas compared to the normal one (p<0.05) (Fig. 4A,
B), that of PlGFR-2 showed no significant difference (Fig. 4C,
D). Relative densities were normalized by  -actin signals.
DISCUSSION
Although many theories have been proposed to explain the
development of PIH, most of previous reports have not pro-
vided a clear picture. What is known, to date, is that PIH
originates in the placenta and involves vasospasm of blood ves-
sels in both mother and the placenta causing damage to the
interior lining of blood vessels; its association with endothelial
damage and dysfunction has been reported (2).
PlGFs, angiogenic growth factors, and their receptors are
essential for placental vascular development (12). In this study,
we examined the expression level of PlGF-1 and PlGF-2
mRNAs in both the normal and PIH placentas at term and
found a decreased mRNA level of PlGF-2 in PIH placentas
by Northern blots and in situ hybridization. This result agrees
well with previous reports; serum PlGF level was significant-
ly lower in PIH as compared to normal pregnancies (18, 19);
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Fig. 3. Localization of PlGF-1 and PlGF-2 mRNA in the normal and PIH (pregnancy induced hypertension) placentas by in situ hybridiza-
tion. (A) and (B) are bright field micrograph with counterstained with hematoxylin. (a)-(d) are directly scanned from radiography autora-
diogram using film scanner and inverted using photoshop (Ver. 5.0) program. PlGF-1 (data not shown) and PlGF-2 mRNAs are expressed
in the vasculosyncytial membrane and villous stroma of the normal (A) and PIH placental villi (B). There is no significant difference in the
expression of PlGF-1 mRNA between the normal (a) and PIH placentas (b). The expression of PlGF-2 mRNA is decreased in the PIH pla-
centa (d) compared to the normal one (c). (original magnification:  2.1). PlGF-1, placenta growth factor -1; PlGF-2, placenta growth fac-
tor -2. Scale bar in A, B= 50  m.
a b c dthe transcription of PlGF-2 mRNA in the placenta and decid-
ua from PIHs decreased significantly (20).
Biological activities of PlGF-2 are mediated by the PlGFR-
1 (21, 22). Three cell types in the placenta express the PlGFR-
1; endothelial cells, Hoffbauer cells and trophoblasts, with
extravillous trophoblast showing particularly high expression
(23). In normal pregnancies, fetal trophoblasts invade the ma-
ternal decidua and remodel the spiral arteries, converting them
to lower resistant vessels. In pregnancies complicated by pre-
eclampsia, this trophoblastic cell invasion is inadequate, result-
ing in poor placental perfusion and fetal hypoxia (24, 25).
The increased syncytial knots in the PIH placenta (Fig. 1)
compared to normal one implicate an inadequate invasion
of trophoblastic cells and this may be caused by a lower level
of PlGF-2.
We revealed higher level of PlGFR-1 in the PIH placenta
compared to normal one using RT-PCR and this was also
consistent with other reports (19, 26); PlGFR-1, but not the
other receptors, showed increased expression in the placental
syncytiotrophoblasts among 50% of patients with severe pre-
eclampsia compared to normal ones (19). Helske et al. (19)
suggested that the increased PlGFR-1 expression is probably
not a specific change of characteristic for pre-eclampsia, but
is possibly associated with abnormal placental function and
hypoxia. It was also revealed that trophoblastic cells express
both insoluble PlGFR-1 and soluble PlGFR-1, and the solu-
ble form PlGFR-1 have an antagonistic regulation function
of its ligands (27). Therefore, the inadequate development
of chorionic villi after mid gestation in PIH placenta may be
possibly due to the lower level of PlGF mRNA and higher
level of PlGFR-1 mRNA.
In the human placenta, VEGF, PlGF and their receptors
are differentially expressed throughout gestation: VEGF and
PlGFR-2 are most intense during early gestation and decline
as pregnancy advances (13-15) while PlGF and PlGFR-1
increase towards term (16, 17). Correlation of these growth-
factor effects and their expression patterns throughout ges-
tation with a development of a villous angioarchitecture (28,
29) suggest that VEGF and PlGFR-2 are involved in the first
two trimesters of pregnancy in the establishment of the rich-
ly branched capillary beds of the mesenchymal and immature
intermediate villi while PlGF and PlGFR-1 are more likely
to be involved in the formation of the long, poorly branched,
terminal capillary loops in the last trimester (30).
Although PlGF itself does not significantly stimulate an-
giogenesis in vivo and in vitro, this growth factor modulates
the angiogenic activity of VEGF by forming PlGF/VEGF
heterodimers (31). Therefore, the amount of VEGF is also im-
portant in complicated placenta etiology. However, recent
reports provide conflicting conclusions regarding the expres-
sion of VEGF in pre-eclamptic pregnancies; at the RNA level,
VEGF expression was found to decrease in single biopsy sam-
ples of pre-eclamptic placentas as compared to biopsies from
normal placentas (32); VEGF protein levels in serum of pre-
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Fig. 4. Quantitative analyses of PlGFR-1 and PlGFR-2 in the normal and PIH placentas by RT-PCR. The product signals at 372 bp and
322 bp represent mRNAs of PlGFR-1 (A) and PlGFR-2 (C), respectively. The expression of PlGFR-1 is significantly greater in the PIH
(pregnancy induced hypertension) placenta compared to controls (p<0.05) (B), while that of PlGFR-2 shows a mild increase (D). Rela-
tive densities were normalized to  -actin. PlGFR-1, placenta growth factor receptor-1; PlGFR-2, placenta growth factor receptor-2.
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Nomal PIHeclamptic women were found to be elevated in some studies
(33, 34) while others have reported decreased levels (35), rel-
ative to normal pregnant women; PlGF homodimers are
themselves angiogenic (36) and may also function to enhance
the activity of suboptimal concentrations of VEGF (21). Fur-
thermore, naturally occurring VEGF/PlGF heterodimers
maintain high-affinity receptor binding and mitogenic activ-
ity on HUVE cells (37). While VEGF binds with high affini-
ty to both PlGFR-2 and PlGFR-1, PlGF exhibits high affin-
ity only to PlGFR-1 (21). Therefore, it is suggested that the
main cause of delicate placental complications is PlGF rather
than VEGF considering its amount consistency in complicat-
ed pregnancy placenta and its specificity to PlGFR-1. Espe-
cially, the adequate PlGF-2 mRNA expression level in pla-
centa seems to be essential for normal placenta morphometric
development in late pregnancy.
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